Devika Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Devika Patel has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Sammann
The Better Lab, University of California San Francisco, San Francisco, California; Department of Surgery, University of California San Francisco, San Francisco, California
17 shared publications - Adithya Cattamanchi
Center for Tuberculosis, Institute for Global Health Sciences, University of California San Francisco , San Francisco, California
8 shared publications - Achilles Katamba
Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
6 shared publications - Christopher Allen Berger
Affiliation Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America
6 shared publications - Joshua Feler
From the Warren Alpert Medical School of Brown University (Z.Z., C.M.P, M.G., R.K., G.K., L.B., J.R.F., E.S., S.C., L.S., G.B., M.J., S.Y., Z.J., D.N.W.), Department of Radiology (Z.Z., G.B., M.J., Z.J.), Brown University Health, Department of Interventional Radiology (D.N.W.), Brown University Health, Department of Neurosurgery (J.R.F.), Brown University Health, Providence 02903, USA
6 shared publications - Lara Chehab
Department of Surgery, University of California, San Francisco, San Francisco, CA, United States
6 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Designing a Client-Facing Mobile Health Application for Survivors of Violence: Mixed Methods Human-Centered Design Study (Preprint)
BACKGROUND Hospital-based violence intervention programs (HVIPs) play a critical role in reducing the long-term impacts of violence by linking survivors to resources that address social needs. However, HVIP effectiveness is often hindered by disorganized communication between Violence Prevention Professionals (VPPs) and their clients. Mobile health (mHealth) tools have the potential to improve communication, but none have been co-designed with survivors of violence to meet their unique needs. This study extends prior mHealth application (app) development aligned with VPP workflows and applies a Human-Centered Design (HCD) approach that deliberately centers the client-facing user experience as a core design input, ensuring that the mHealth app reflects clients' lived realities, preferences, and barriers to engagement. OBJECTIVE This study aims to design an mHealth app to improve communication and access to resources for survivors of violence using human-centered design (HCD) and iterative prototyping methods. METHODS We developed the client-facing component using human-centered design and integrated three ‘Ideation Phase’ methods: Participatory Design, Low-Fidelity Prototype Testing, and High-Fidelity Prototype Testing. The Participatory Design phase included semi-structured interviews and co-design activities with clients, followed by inductive qualitative analysis to inform the app's initial low-fidelity design. The Low-Fidelity Prototype Testing phase included guided user-testing interviews with probing questions about static wireframes, followed by inductive qualitative analysis to inform the app's initial high-fidelity design. The High-Fidelity Prototype Testing phase utilized the Rapid Iterative Testing and Evaluation (RITE) method. An impact ratio was calculated to quantify the proportion of identified usability issues that were successfully addressed through iterative design changes. RESULTS Fifteen unique clients participated across 16 testing sessions (one client participated in two phases). Participatory Design identified six key themes: (1) trust, (2) personal connection, (3) guidance in meaningful decision-making, (4) client empowerment, (5) intuitive and comprehensive design, and (6) dynamic journey and sense of progress. Low-Fidelity Testing reinforced these themes and identified two additional themes: (7) app personalization and (8) tailored resource curation. High-Fidelity Testing reinforced themes 1-8 and uncovered seven more: (9) celebration of client successes, (10) standardization of verbiage and design choices, (11) control over boundaries, (12) legitimization of experience, (13) accessibility of VPPs, (14) gratitude expression, and (15) integration with medical care. High-Fidelity Prototype Testing through RITE identified 98 actionable issues, with 89 addressed, achieving a 91% impact ratio. The final iteration of the app expanded from 12 initial low-fidelity wireframes to 32 refined high-fidelity wireframes designed to support client recovery from violent injury. CONCLUSIONS The study used HCD and RITE to develop and refine a client-facing app tailored to survivors of violence receiving HVIP case management services. The 91% impact ratio indicates that RITE supported rapid prioritization and resolution of usability issues. The final version of the app integrates core features that enhance usability, empowerment, connection, decision-making, and support while ensuring accessibility and consistency for clients. This approach may be adaptable to developing other mHealth tools for specialized populations, though further research in other settings and with larger samples is needed to assess generalizability.
- 20 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDesigning a Client-Facing Mobile Health Application for Survivors of Violence: Mixed Methods Human-Centered Design Study (Preprint)
BACKGROUND Hospital-based violence intervention programs (HVIPs) play a critical role in reducing the long-term impacts of violence by linking survivors to resources that address social needs. However, HVIP effectiveness is often hindered by disorganized communication between Violence Prevention Professionals (VPPs) and their clients. Mobile health (mHealth) tools have the potential to improve communication, but none have been co-designed with survivors of violence to meet their unique needs. This study extends prior mHealth application (app) development aligned with VPP workflows and applies a Human-Centered Design (HCD) approach that deliberately centers the client-facing user experience as a core design input, ensuring that the mHealth app reflects clients' lived realities, preferences, and barriers to engagement. OBJECTIVE This study aims to design an mHealth app to improve communication and access to resources for survivors of violence using human-centered design (HCD) and iterative prototyping methods. METHODS We developed the client-facing component using human-centered design and integrated three ‘Ideation Phase’ methods: Participatory Design, Low-Fidelity Prototype Testing, and High-Fidelity Prototype Testing. The Participatory Design phase included semi-structured interviews and co-design activities with clients, followed by inductive qualitative analysis to inform the app's initial low-fidelity design. The Low-Fidelity Prototype Testing phase included guided user-testing interviews with probing questions about static wireframes, followed by inductive qualitative analysis to inform the app's initial high-fidelity design. The High-Fidelity Prototype Testing phase utilized the Rapid Iterative Testing and Evaluation (RITE) method. An impact ratio was calculated to quantify the proportion of identified usability issues that were successfully addressed through iterative design changes. RESULTS Fifteen unique clients participated across 16 testing sessions (one client participated in two phases). Participatory Design identified six key themes: (1) trust, (2) personal connection, (3) guidance in meaningful decision-making, (4) client empowerment, (5) intuitive and comprehensive design, and (6) dynamic journey and sense of progress. Low-Fidelity Testing reinforced these themes and identified two additional themes: (7) app personalization and (8) tailored resource curation. High-Fidelity Testing reinforced themes 1-8 and uncovered seven more: (9) celebration of client successes, (10) standardization of verbiage and design choices, (11) control over boundaries, (12) legitimization of experience, (13) accessibility of VPPs, (14) gratitude expression, and (15) integration with medical care. High-Fidelity Prototype Testing through RITE identified 98 actionable issues, with 89 addressed, achieving a 91% impact ratio. The final iteration of the app expanded from 12 initial low-fidelity wireframes to 32 refined high-fidelity wireframes designed to support client recovery from violent injury. CONCLUSIONS The study used HCD and RITE to develop and refine a client-facing app tailored to survivors of violence receiving HVIP case management services. The 91% impact ratio indicates that RITE supported rapid prioritization and resolution of usability issues. The final version of the app integrates core features that enhance usability, empowerment, connection, decision-making, and support while ensuring accessibility and consistency for clients. This approach may be adaptable to developing other mHealth tools for specialized populations, though further research in other settings and with larger samples is needed to assess generalizability.
- Open Access
- 2 February 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10 (1) , e79533
Designing a Case Management Mobile Health App for Violence Intervention Programs: Mixed Methods Human-Centered Design Study
Background: Hospital-based violence intervention programs have shown promise in mitigating the effects of violence, but their impact is limited by time constraints and inefficient practices faced by the violence prevention professionals (VPPs) who function as case managers. Mobile health (mHealth) apps offer the potential to enhance communication and service delivery between VPPs and clients, but few have been specifically designed for vulnerable populations. Objective: This study aims to design an mHealth app to improve communication and access to resources between survivors of violence and their VPPs using human-centered design (HCD) and iterative prototyping methods. Methods: HCD methodology was used, including rounds of Participatory Design, Low-fidelity Prototype Testing, and High-fidelity Prototype Testing. The Participatory Design phase included in-depth interviews and co-design, followed by inductive qualitative analysis to inform the mHealth app’s initial low-fidelity design. The Low-fidelity Prototype Testing phase included in-depth interviews with probing questions about the low-fidelity design, followed by inductive qualitative analysis to inform the mHealth app’s initial high-fidelity design. The High-fidelity Prototype Testing phase used the Rapid Iterative Testing and Evaluation (RITE) method and inductive qualitative analysis to rapidly collect and integrate VPP feedback into the mHealth app’s final design approved for implementation. Results: Nine VPPs participated in 3 rounds of testing and feedback. Participatory Design identified four key themes: (1) trust, (2) personal connection, (3) tailored resource curation , and (4) management of administrative burdens. Low-fidelity Prototype Testing identified three additional key themes: (5) intuitive and comprehensive design, (6) dynamic journey and sense of progress, and (7) standardization of verbiage and design choices. High-fidelity Prototype Testing through RITE identified 181 actionable issues, with 133 addressed, achieving a 73% impact ratio (used to measure the effectiveness of usability improvements). High-fidelity Prototype Testing identified 9 key themes, reaffirming 5 themes from prior testing sessions (themes 2, 3, 5, 6, and 7) and uncovering four novel themes: (8) control over boundaries, (9) celebration of client successes, (10) client empowerment, and (11) warm handoff. The final mHealth app version adapted from 3 low-fidelity digital representations (wireframes) to 25 high-fidelity wireframes of a mHealth app to support case management. Conclusions: The combination of HCD and RITE methodologies resulted in an mHealth app tailored to the needs of VPPs working with survivors of violence. This approach may be transferable to the development of other mHealth apps for specialized populations, although further research with larger samples would be needed to establish generalizability.
- 2 February 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10 (1) , e79533
Open AccessDesigning a Case Management Mobile Health App for Violence Intervention Programs: Mixed Methods Human-Centered Design Study
Background: Hospital-based violence intervention programs have shown promise in mitigating the effects of violence, but their impact is limited by time constraints and inefficient practices faced by the violence prevention professionals (VPPs) who function as case managers. Mobile health (mHealth) apps offer the potential to enhance communication and service delivery between VPPs and clients, but few have been specifically designed for vulnerable populations. Objective: This study aims to design an mHealth app to improve communication and access to resources between survivors of violence and their VPPs using human-centered design (HCD) and iterative prototyping methods. Methods: HCD methodology was used, including rounds of Participatory Design, Low-fidelity Prototype Testing, and High-fidelity Prototype Testing. The Participatory Design phase included in-depth interviews and co-design, followed by inductive qualitative analysis to inform the mHealth app’s initial low-fidelity design. The Low-fidelity Prototype Testing phase included in-depth interviews with probing questions about the low-fidelity design, followed by inductive qualitative analysis to inform the mHealth app’s initial high-fidelity design. The High-fidelity Prototype Testing phase used the Rapid Iterative Testing and Evaluation (RITE) method and inductive qualitative analysis to rapidly collect and integrate VPP feedback into the mHealth app’s final design approved for implementation. Results: Nine VPPs participated in 3 rounds of testing and feedback. Participatory Design identified four key themes: (1) trust, (2) personal connection, (3) tailored resource curation , and (4) management of administrative burdens. Low-fidelity Prototype Testing identified three additional key themes: (5) intuitive and comprehensive design, (6) dynamic journey and sense of progress, and (7) standardization of verbiage and design choices. High-fidelity Prototype Testing through RITE identified 181 actionable issues, with 133 addressed, achieving a 73% impact ratio (used to measure the effectiveness of usability improvements). High-fidelity Prototype Testing identified 9 key themes, reaffirming 5 themes from prior testing sessions (themes 2, 3, 5, 6, and 7) and uncovering four novel themes: (8) control over boundaries, (9) celebration of client successes, (10) client empowerment, and (11) warm handoff. The final mHealth app version adapted from 3 low-fidelity digital representations (wireframes) to 25 high-fidelity wireframes of a mHealth app to support case management. Conclusions: The combination of HCD and RITE methodologies resulted in an mHealth app tailored to the needs of VPPs working with survivors of violence. This approach may be transferable to the development of other mHealth apps for specialized populations, although further research with larger samples would be needed to establish generalizability.
- Open Access
- 24 June 2025
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 12 (1) , e66854
Understanding Barriers to Home Safety Assessment Adoption in Older Adults: Qualitative Human-Centered Design Study
Background: Falls are the leading cause of injury-related death among adults aged 65 and older. The fear of falling can further limit older adults’ independence by contributing to activity restriction, social isolation, and physical decline—ironically increasing the risk of mechanical falls. Although home safety assessments have been shown to reduce fall risk by up to 36% and decrease serious injuries such as hip fractures, their adoption remains low. Understanding the barriers to implementing these assessments is critical to improving their uptake and effectiveness. Objective: This study aimed to (1) identify specific barriers perceived by older adults in implementing home safety assessments and modifications to reduce the risk of mechanical falls, (2) explore the attitudes of health care professionals and other stakeholders toward these assessments, and (3) identify novel design opportunities to guide the development and implementation of more effective home safety assessment techniques and practices to reduce mechanical fall risk. Methods: This explanatory qualitative study drew on the “inspiration” phase of the human-centered design (HCD) research process. We conducted 35 interviews (28 initial and 7 follow-up) with 28 purposefully sampled participants in the San Francisco Bay Area between February and June 2021. Participants included community-dwelling older adults (n=3), geriatricians (n=4), therapists (n=6), product developers (n=2), older health researchers (n=8), and community program leaders (n=5). Interview notes were analyzed inductively by the research team to extract themes and generate insight statements and design opportunities. Results: Analysis yielded three key insights: (1) older adults often experience a conflict between maintaining independence and implementing safety modifications. One participant described living with a “repeating mantra in my head throughout the day saying ‘above all, don’t fall.’” (2) aesthetic and privacy concerns frequently override safety benefits. Participants rejected modifications that made their homes feel “institutional.” (3) access to occupational therapy services—already limited in rural areas—was further constrained by the COVID-19 pandemic, with some providers reporting that travel time “took up the majority of their day just assessing one home.” These barriers help explain the low adoption of home safety assessments despite strong supporting evidence. The study identified design opportunities to address these challenges, including customizable, user-friendly safety solutions, dignity-preserving approaches to assessment, and technology-enabled remote alternatives. Conclusions: This study identified specific emotional, aesthetic, logistical, and access-related barriers to the adoption of home safety assessments among older adults. The proposed design solutions offer promising directions to increase uptake, improve user experience, and enhance safety. However, further validation through co-design with a larger and more diverse group of older adults is needed. Future research should pilot test these ideas across varied contexts and evaluate their implementation and impact.
- 24 June 2025
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 12 (1) , e66854
Open AccessUnderstanding Barriers to Home Safety Assessment Adoption in Older Adults: Qualitative Human-Centered Design Study
Background: Falls are the leading cause of injury-related death among adults aged 65 and older. The fear of falling can further limit older adults’ independence by contributing to activity restriction, social isolation, and physical decline—ironically increasing the risk of mechanical falls. Although home safety assessments have been shown to reduce fall risk by up to 36% and decrease serious injuries such as hip fractures, their adoption remains low. Understanding the barriers to implementing these assessments is critical to improving their uptake and effectiveness. Objective: This study aimed to (1) identify specific barriers perceived by older adults in implementing home safety assessments and modifications to reduce the risk of mechanical falls, (2) explore the attitudes of health care professionals and other stakeholders toward these assessments, and (3) identify novel design opportunities to guide the development and implementation of more effective home safety assessment techniques and practices to reduce mechanical fall risk. Methods: This explanatory qualitative study drew on the “inspiration” phase of the human-centered design (HCD) research process. We conducted 35 interviews (28 initial and 7 follow-up) with 28 purposefully sampled participants in the San Francisco Bay Area between February and June 2021. Participants included community-dwelling older adults (n=3), geriatricians (n=4), therapists (n=6), product developers (n=2), older health researchers (n=8), and community program leaders (n=5). Interview notes were analyzed inductively by the research team to extract themes and generate insight statements and design opportunities. Results: Analysis yielded three key insights: (1) older adults often experience a conflict between maintaining independence and implementing safety modifications. One participant described living with a “repeating mantra in my head throughout the day saying ‘above all, don’t fall.’” (2) aesthetic and privacy concerns frequently override safety benefits. Participants rejected modifications that made their homes feel “institutional.” (3) access to occupational therapy services—already limited in rural areas—was further constrained by the COVID-19 pandemic, with some providers reporting that travel time “took up the majority of their day just assessing one home.” These barriers help explain the low adoption of home safety assessments despite strong supporting evidence. The study identified design opportunities to address these challenges, including customizable, user-friendly safety solutions, dignity-preserving approaches to assessment, and technology-enabled remote alternatives. Conclusions: This study identified specific emotional, aesthetic, logistical, and access-related barriers to the adoption of home safety assessments among older adults. The proposed design solutions offer promising directions to increase uptake, improve user experience, and enhance safety. However, further validation through co-design with a larger and more diverse group of older adults is needed. Future research should pilot test these ideas across varied contexts and evaluate their implementation and impact.
- 23 April 2025
- Published by Elsevier in Disability and Health Journal
- Vol. 18 (4) , 101840
Inclusivity in Design: Integrating human-centered methodologies in disability research
- 23 April 2025
- Published by Elsevier in Disability and Health Journal
- Vol. 18 (4) , 101840
Inclusivity in Design: Integrating human-centered methodologies in disability research
- 12 March 2025
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 100 (7) , 761
Questioning the Value of Prompt Engineering in Medical Education
An abstract is unavailable. This article is available as a PDF only.
- 12 March 2025
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 100 (7) , 761
Questioning the Value of Prompt Engineering in Medical Education
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 29 November 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 69 (3) , e228-e239
Using Human-Centered Design to Improve Serious Illness Care for Older Adults With Advanced Dementia
- 29 November 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 69 (3) , e228-e239
Open AccessUsing Human-Centered Design to Improve Serious Illness Care for Older Adults With Advanced Dementia
- Open Access
- 24 October 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (10) , e0003347
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We used thematic analysis (inductive and deductive) to align the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as needed enabled acceptance of patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, prior TPT experience with daily isoniazid, and few 3HP-related serious adverse events enabled adoption, whereas initial concerns about 3HP safety among HCPs, and COVID-19 treatment disruptions delayed 3HP adoption. Refresher training and collaboration among HCPs enabled implementation whereas limited diagnostic facilities for adverse events at the clinic hindered implementation. SAT was modified post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up. Trial registration: ClinicalTrials.gov (NCT03934931); Registered 2nd May 2019; https://clinicaltrials.gov/study/NCT03934931?id = NCT03934931&rank = 1.
- 24 October 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (10) , e0003347
Open AccessEvaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We used thematic analysis (inductive and deductive) to align the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as needed enabled acceptance of patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, prior TPT experience with daily isoniazid, and few 3HP-related serious adverse events enabled adoption, whereas initial concerns about 3HP safety among HCPs, and COVID-19 treatment disruptions delayed 3HP adoption. Refresher training and collaboration among HCPs enabled implementation whereas limited diagnostic facilities for adverse events at the clinic hindered implementation. SAT was modified post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up. Trial registration: ClinicalTrials.gov (NCT03934931); Registered 2nd May 2019; https://clinicaltrials.gov/study/NCT03934931?id = NCT03934931&rank = 1.
- Open Access
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We conducted an inductive thematic analysis and aligned the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as required enabled acceptance for patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, and collaboration among HCPs enabled, whereas initial concerns about 3HP safety among HCPs delayed 3HP adoption and implementation. SAT was maintained post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up.
Open AccessEvaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We conducted an inductive thematic analysis and aligned the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as required enabled acceptance for patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, and collaboration among HCPs enabled, whereas initial concerns about 3HP safety among HCPs delayed 3HP adoption and implementation. SAT was maintained post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up.
- Open Access
- 20 February 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (2) , e1004356
Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial
Background: Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance and completion of 3HP could be achieved with delivery strategies optimized to overcome well-contextualized barriers and that 3HP acceptance and completion would be highest when PLHIV were provided an informed choice between delivery strategies. Methods and findings: In a pragmatic, single-center, 3-arm, parallel-group randomized trial, PLHIV receiving care at a large urban HIV clinic in Kampala, Uganda, were randomly assigned (1:1:1) to receive 3HP by facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between facilitated DOT and facilitated SAT using a shared decision-making aid. We assessed the primary outcome of acceptance and completion (≥11 of 12 doses of 3HP) within 16 weeks of treatment initiation using proportions with exact binomial confidence intervals (CIs). We compared proportions between arms using Fisher’s exact test (two-sided α = 0.025). Trial investigators were blinded to primary and secondary outcomes by study arm. Between July 13, 2020, and July 8, 2022, 1,656 PLHIV underwent randomization, with equal numbers allocated to each study arm. One participant was erroneously enrolled a second time and was excluded in the primary intention-to-treat analysis. Among the remaining 1,655 participants, the proportion who accepted and completed 3HP exceeded the prespecified 80% target in the DOT (0.94; 97.5% CI [0.91, 0.96] p < 0.001), SAT (0.92; 97.5% CI [0.89, 0.94] p < 0.001), and Choice (0.93; 97.5% CI [0.91, 0.96] p < 0.001) arms. There was no difference in acceptance and completion between any 2 arms overall or in prespecified subgroup analyses based on sex, age, time on antiretroviral therapy, and history of prior treatment for TB or TB infection. Only 14 (0.8%) participants experienced an adverse event prompting discontinuation of 3HP. The main limitation of the study is that it was conducted in a single center. Multicenter studies are now needed to confirm the feasibility and generalizability of the facilitated 3HP delivery strategies in other settings. Conclusions: Short-course TB preventive treatment was widely accepted by PLHIV in Uganda, and very high levels of treatment completion were achieved in a programmatic setting with delivery strategies tailored to address known barriers. Trial Registration: ClinicalTrials.gov NCT03934931.
- 20 February 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (2) , e1004356
Open AccessComparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial
Background: Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance and completion of 3HP could be achieved with delivery strategies optimized to overcome well-contextualized barriers and that 3HP acceptance and completion would be highest when PLHIV were provided an informed choice between delivery strategies. Methods and findings: In a pragmatic, single-center, 3-arm, parallel-group randomized trial, PLHIV receiving care at a large urban HIV clinic in Kampala, Uganda, were randomly assigned (1:1:1) to receive 3HP by facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between facilitated DOT and facilitated SAT using a shared decision-making aid. We assessed the primary outcome of acceptance and completion (≥11 of 12 doses of 3HP) within 16 weeks of treatment initiation using proportions with exact binomial confidence intervals (CIs). We compared proportions between arms using Fisher’s exact test (two-sided α = 0.025). Trial investigators were blinded to primary and secondary outcomes by study arm. Between July 13, 2020, and July 8, 2022, 1,656 PLHIV underwent randomization, with equal numbers allocated to each study arm. One participant was erroneously enrolled a second time and was excluded in the primary intention-to-treat analysis. Among the remaining 1,655 participants, the proportion who accepted and completed 3HP exceeded the prespecified 80% target in the DOT (0.94; 97.5% CI [0.91, 0.96] p < 0.001), SAT (0.92; 97.5% CI [0.89, 0.94] p < 0.001), and Choice (0.93; 97.5% CI [0.91, 0.96] p < 0.001) arms. There was no difference in acceptance and completion between any 2 arms overall or in prespecified subgroup analyses based on sex, age, time on antiretroviral therapy, and history of prior treatment for TB or TB infection. Only 14 (0.8%) participants experienced an adverse event prompting discontinuation of 3HP. The main limitation of the study is that it was conducted in a single center. Multicenter studies are now needed to confirm the feasibility and generalizability of the facilitated 3HP delivery strategies in other settings. Conclusions: Short-course TB preventive treatment was widely accepted by PLHIV in Uganda, and very high levels of treatment completion were achieved in a programmatic setting with delivery strategies tailored to address known barriers. Trial Registration: ClinicalTrials.gov NCT03934931.